Boeve, B. F. Parkinson-related dementias. Neurol. Clin. 25, 761–781 (2007).
Litvan, I. et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J. Neuropathol. Exp. Neurol. 55, 97–105 (1996).
Williams, D. R. & Lees, A. J. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 8, 270–279 (2009).
Dickson, D. W. Neuropathology of progressive supranuclear palsy. Handb. Clin. Neurol. 89, 487–491 (2008).
Litvan, I. et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47, 1–9 (1996).
Chung, D.-E. C., Roemer, S., Petrucelli, L. & Dickson, D. W. Cellular and pathological heterogeneity of primary tauopathies. Mol. Neurodegener. 16, 57–57 (2021).
Williams, D. R. et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 130, 1566–1576 (2007).
Wilson, D., Le Heron, C. & Anderson, T. Corticobasal syndrome: a practical guide. Pract. Neurol. 21, 276 (2021).
Armstrong, M. J. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80, 496–503 (2013).
Whitwell, J. L. et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 75, 1879–1887 (2010).
Cordato, N. J. et al. Corticobasal syndrome with tau pathology. Mov. Disord. 16, 656–667 (2001).
Kim, E.-J. et al. Evidence of corticofugal tau spreading in patients with frontotemporal dementia. Acta Neuropathol. 139, 27–43 (2020).
Whiteside, D. J. et al. Altered network stability in progressive supranuclear palsy. Neurobiol. Aging 107, 109–117 (2021).
Stamelou, M. et al. Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nat. Rev. Neurol. 17, 601–620 (2021).
Clavaguera, F. et al. “Prion-like” templated misfolding in tauopathies. Brain Pathol. 23, 342–349 (2013).
Duquette, A., Pernègre, C., Veilleux Carpentier, A. & Leclerc, N. Similarities and differences in the pattern of tau hyperphosphorylation in physiological and pathological conditions: impacts on the elaboration of therapies to prevent tau pathology. Front. Neurol. 11, 607680 (2020).
Cagney, D. N. et al. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro Oncol. 20, 1162–1172 (2018).
Raffelt, D. A. et al. Investigating white matter fibre density and morphology using fixel-based analysis. Neuroimage 144, 58–73 (2017).
Dutt, S. et al. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology 87, 2016–2025 (2016).
Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695–699 (2005).
Saito, Y. et al. Temporal progression patterns of brain atrophy in corticobasal syndrome and progressive supranuclear palsy revealed by Subtype and Stage Inference (SuStaIn). Front. Neurol. 13, 814768 (2022).
Whitwell, J. L. et al. Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat. Disord. 20, 493–498 (2014).
Jeurissen, B., Leemans, A., Tournier, J. D., Jones, D. K. & Sijbers, J. Investigating the prevalence of complex fiber configurations in white matter tissue with diffusion magnetic resonance imaging. Hum. Brain Mapp. 34, 2747–2766 (2013).
Raffelt, D. A. et al. Connectivity-based fixel enhancement: whole-brain statistical analysis of diffusion MRI measures in the presence of crossing fibres. Neuroimage 117, 40–55 (2015).
Nguyen, T.-T. et al. Fixel-based analysis of white matter degeneration in patients with progressive supranuclear palsy or multiple system atrophy, as compared to Parkinson’s disease. Front. Aging Neurosci. 13, 625874 (2021).
Sakamoto, S. et al. Dentatorubrothalamic tract reduction using fixel-based analysis in corticobasal syndrome. Neuroradiology 63, 529–538 (2021).
Ling, H. et al. Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain 139, 3237–3252 (2016).
Kouri, N. et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 134, 3264–3275 (2011).
Raffelt, D. et al. Apparent Fibre Density: a novel measure for the analysis of diffusion-weighted magnetic resonance images. Neuroimage 59, 3976–3994 (2012).
Tsuboi, Y. et al. Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 60, 1766–1769 (2003).
Ouchi, H. et al. Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov. Disord. 29, 238–244 (2014).
Lee, S. E. et al. Clinicopathological correlations in corticobasal degeneration. Ann. Neurol. 70, 327–340 (2011).
Leuzy, A. et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Mol. Psychiatry 24, 1112–1134 (2019).
Kovacs, G. G. et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 140, 99–119 (2020).
Forman, M. S. et al. Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am. J. Pathol. 160, 2045–2053 (2002).
Ling, H. et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol. Appl. Neurobiol. 40, 149–163 (2014).
Mitchell, T. et al. Advanced diffusion imaging to track progression in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neuroimage Clin. 34, 103022 (2022).
Seki, M. et al. Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. Parkinsonism Relat. Disord. 49, 81–87 (2018).
Meola, A., Comert, A., Yeh, F. C., Sivakanthan, S. & Fernandez-Miranda, J. C. The nondecussating pathway of the dentatorubrothalamic tract in humans: human connectome-based tractographic study and microdissection validation. J. Neurosurg. 124, 1406–1412 (2016).
Petersen, K. J. et al. Structural and functional connectivity of the nondecussating dentato-rubro-thalamic tract. Neuroimage 176, 364–371 (2018).
Ishizawa, K. et al. A qualitative and quantitative study of grumose degeneration in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 59, 513–524 (2000).
Josephs, K. A. et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration. J. Neuropathol. Exp. Neurol. 65, 396–405 (2006).
Whitwell, J. L. et al. Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch. Neurol. 68, 753–760 (2011).
Whitwell, J. L. et al. Imaging measures predict progression in progressive supranuclear palsy. Mov. Disord. 27, 1801–1804 (2012).
Sintini, I. et al. Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. Neuroimage Clin. 32, 102850 (2021).
Alam, M., Schwabe, K. & Krauss, J. K. The pedunculopontine nucleus area: critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation. Brain 134, 11–23 (2011).
Murray, R. et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 68, 1274–1283 (2007).
Day, G. S. et al. Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology 88, 1273–1281 (2017).
Zhang, Y. et al. Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: a longitudinal diffusion tensor imaging study. PLoS ONE 11, e0157218 (2016).
Ling, H. et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133, 2045–2057 (2010).
Niccolini, F. et al. Disease-related patterns of in vivo pathology in Corticobasal syndrome. Eur. J. Nucl. Med. Mol. Imaging 45, 2413–2425 (2018).
Upadhyay, N. et al. MRI gray and white matter measures in progressive supranuclear palsy and corticobasal syndrome. J. Neurol. 263, 2022–2031 (2016).
Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313, 1939–1949 (2015).
Palleis, C. et al. Cortical [(18) F]PI-2620 binding differentiates corticobasal syndrome subtypes. Mov. Disord. 36, 2104–2115 (2021).
Toledo, J. B. et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 124, 23–35 (2012).
Constantinides, V. C. et al. MRI planimetry and magnetic resonance Parkinsonism Index in the differential diagnosis of patients with Parkinsonism. AJNR Am. J. Neuroradiol. 39, 1047–1051 (2018).
Dhollander, T. & Connelly, A. A novel iterative approach to reap the benefits of multi-tissue CSD from just single-shell (+b = 0) diffusion MRI data. In Proc. 24th International Society of Magnetic Resonance in Medicine (2016).
Aerts, H., Dhollander, T. & Marinazzo, D. Evaluating the performance of 3-tissue constrained spherical deconvolution pipelines for within-tumor tractography. Preprint at bioRxiv https://doi.org/10.1101/629873 (2019).
Genc, S. et al. Impact of b-value on estimates of apparent fibre density. Hum. Brain Mapp. 41, 2583–2595 (2020).
Andica, C. et al. Fiber-specific white matter alterations in early-stage tremor-dominant Parkinson’s disease. NPJ Parkinsons Dis. 7, 51 (2021).
Boxer, A. L. et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 13, 676–685 (2014).
Burn, D. J. Clinical assessment of progressive supranuclear palsy over time: new rating scale validated. Nat. Clin. Pr. Neurol. 3, 600–601 (2007).
Folstein, M. F., Folstein, S. E. & McHugh, P. R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975).
Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170 (2008).
Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412–2414 (1993).
Schwab, J. F. & England, A. C. Projection technique for evaluating surgery in Parkinson’s disease. In Proc. Third Symposium on Parkinson’s Disease (eds Gillingham, F. J. & Donaldson, M. C.) (Churchill Livingstone, 1969).
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H. Jr, Chance, J. M. & Filos, S. Measurement of functional activities in older adults in the community. J. Gerontol. 37, 323–329 (1982).
Basser, P. J., Mattiello, J. & LeBihan, D. MR diffusion tensor spectroscopy and imaging. Biophys. J. 66, 259–267 (1994).
Veraart, J., Fieremans, E. & Novikov, D. S. Diffusion MRI noise mapping using random matrix theory. Magn. Reson. Med. 76, 1582–1593 (2016).
Kellner, E., Dhital, B., Kiselev, V. G. & Reisert, M. Gibbs-ringing artifact removal based on local subvoxel-shifts. Magn. Reson. Med. 76, 1574–1581 (2016).
Andersson, J. L. R. & Sotiropoulos, S. N. An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. Neuroimage 125, 1063–1078 (2016).
Tustison, N. J. et al. N4ITK: improved N3 bias correction. IEEE Trans. Med. Imaging 29, 1310–1320 (2010).
Tournier, J. D. et al. MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation. Neuroimage 202, 116137 (2019).
Dhollander, T., Mito, M., Raffelt, D. & Connelly, A. Improved white matter response function estimation for 3-tissue constrained spherical deconvolution. In Proc. 27th International Society of Magnetic Resonance in Medicine, 555 (2019).
Raffelt, D. et al. Symmetric diffeomorphic registration of fibre orientation distributions. Neuroimage 56, 1171–1180 (2011).
Smith, R. E., Tournier, J. D., Calamante, F. & Connelly, A. SIFT: spherical-deconvolution informed filtering of tractograms. Neuroimage 67, 298–312 (2013).
Genc, S. et al. Development of white matter fibre density and morphology over childhood: a longitudinal fixel-based analysis. Neuroimage 183, 666–676 (2018).
Wasserthal, J., Neher, P. & Maier-Hein, K. H. TractSeg—fast and accurate white matter tract segmentation. Neuroimage 183, 239–253 (2018).
Dickson, D. W. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J. Neurol. 246, II6–II15 (1999).
Ashburner, J. & Friston, K. J. Voxel-based morphometry—the methods. Neuroimage 11, 805–821 (2000).
Draganski, B. et al. Regional specificity of MRI contrast parameter changes in normal ageing revealed by voxel-based quantification (VBQ). Neuroimage 55, 1423–1434 (2011).
Dale, A. M., Fischl, B. & Sereno, M. I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 9, 179–194 (1999).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Methodol. 57, 289–300 (1995).